Tech Company Financing Transactions
Generate Biomedicines Funding Round
Generate Biomedicines, operating out of Cambridge, received $273 million from Abu Dhabi Investment Authority, Additionally and Amgen Ventures.
Transaction Overview
Company Name
Announced On
9/15/2023
Transaction Type
Venture Equity
Amount
$273,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to further advance its pipeline, including filing multiple INDs in 2024, and initiating multiple clinical trials annually thereafter, as well as to validate its platform capabilities and establish its leadership in de novo therapeutic development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
26 Landsdowne St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Founded in 2018 by Flagship Pioneering, Generate Biomedicines is the latest in a long line of unprecedented multi-product platform companies like Moderna Therapeutics, Rubius Therapeutics, Indigo Agriculture, and Sana Biotechnology. These companies have pioneered breakthroughs in a variety of life sciences fields.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Nally
Chief Scientific Officer
Michael Nohaile
Chief Technical Officer
Gevorg Grigoryan
Vice President
Kristen Hopson
Vice President
Adam Root
VP - Bus. Development
Molly Gibson
Browse more venture capital transactions:
Prev: 9/15/2023: Evolectric venture capital transaction
Next: 9/15/2023: Lumber venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs